China Southern Power Grid Showcases Multiple AI Achievements at 2025 World Artificial Intelligence Conference
In recent years, CSG embraced emerging technologies—particularly artificial intelligence—and achieved a number of breakthrough advances. These include strengthening its technological foundation, deploying a wide range of demonstration scenarios, and helping build an AI ecosystem within the power sector. These efforts have played a key role in building the New Energy System and the New Power System and serving the industry's transition to low-carbon and environmentally responsible operations.
Looking ahead, CSG will continue to prioritize national strategic objectives, including the Digital China initiative and the broader energy transition. The company plans to deepen its research into AI technologies and expand their application across the energy sector, while strengthening collaboration across the industry value chain. Through these efforts, CSG aims to contribute Chinese solutions and expertise to the global digital and intelligent transformation of the energy industry, and to the long-term goals of carbon peaking and carbon neutrality.
View original content to download multimedia:https://www.prnewswire.com/news-releases/china-southern-power-grid-showcases-multiple-ai-achievements-at-2025-world-artificial-intelligence-conference-302516883.html
SOURCE China Southern Power Grid (CSG)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Cool Off This August with Root Beer Ice Cream at Cold Stone Creamery®
SCOTTSDALE, Ariz., Aug. 1, 2025 /PRNewswire/ -- Cold Stone Creamery® ( is bringing nostalgic flavors to the forefront this summer with the launch of its limited-time Root Beer Ice Cream, available now through August 31. Inspired by the classic soda fountain favorite, this flavor offers a refreshing and creamy twist on a beloved American tradition. Root Beer Ice Cream is handcrafted fresh in every store and can be enjoyed on its own or as part of two delicious offerings. The Root Beer Revival Creation™ mixes Root Beer Ice Cream with chocolate chips, caramel, and whipped topping, while the Go With the Float, our take on the classic soda shop root beer float, features Root Beer Ice Cream and root beer topped with whipped topping and a maraschino cherry. "Root Beer Ice Cream is a nostalgic flavor that instantly takes you back in time," said Courtney Maxedon VP of Marketing and Digital Strategy at Kahala Brands™, parent company of Cold Stone Creamery. "We wanted to capture that classic root beer float experience and serve it up in a way that only Cold Stone can - bold, creamy, and full of flavor." Don't miss your chance to experience this limited-time flavor. Whether you're reliving childhood memories or discovering root beer in a whole new way, our Root Beer Ice Cream is the perfect way to cool off your August. Available in stores and online, this ice cream won't be around for long, so grab it while you can! Promotional Flavor: Root Beer Ice Cream Promotional Creation™: Root Beer Revival - Root Beer Ice Cream, Chocolate Chips, Caramel & Whipped Topping Promotional Float: Go With the Float - Root Beer Ice Cream, Root Beer, Whipped Topping & a Maraschino Cherry About Cold Stone CreameryCold Stone Creamery® delivers the Ultimate Ice Cream Experience® through a community of franchisees who are passionate about ice cream. The secret recipe for smooth and creamy ice cream is handcrafted fresh daily in each store, and then customized by combining a variety of mix-ins on a frozen granite stone. Headquartered in Scottsdale, Arizona, Cold Stone Creamery is owned by parent company Kahala Brands™, one of the fastest growing franchising companies in the world with a portfolio of nearly 30 fast-casual and quick-service restaurant brands with approximately 3,000 locations in 35 countries. The Cold Stone Creamery brand operates nearly 1,500 locations globally in approximately 30 countries worldwide. For more information about Cold Stone Creamery, visit View original content to download multimedia: SOURCE Cold Stone Creamery Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025
BELLEVUE, Wash., Aug. 1, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical innovations to improve health and wellness worldwide, today announced that it will host a Virtual Investor Event on Wednesday, August 6, 2025 at 8:00 a.m. Eastern Time (2:00 p.m. Central European Summer Time / 9:00 p.m. Korea Standard Time). The event will provide shareholders and prospective investors with a detailed update of the Company's strategic direction, subsidiary performance, capital allocation, and pipeline R&D. Senior members of the OSRH executive team will be presenting. Event Details Date: Wednesday, August 6, 2025Time: 8:00 a.m. ET / 2:00 p.m. CEST / 9:00 p.m. KSTLocation: Virtual (livestream access)Registration: Opens Monday, August 4 at Available after the event on the OSR Holdings Investor Relations website. Agenda Highlights Corporate overview and strategic vision Subsidiary and R&D pipeline updates: Vaximm: Tailored, Antigen-specific in vivo T-cell Immunotherapies Darnatein: DRT101 – a potent DMOAD candidate Woori IO acquisition: The opportunity for noninvasive CGM Equity Line of Credit (ELOC) financing strategy Blockchain & Tokenization strategy Live Q&A with management "This event is a timely opportunity to engage with our shareholders and the broader investment community as we move into a transformative stage in OSR's growth," said Peter Hwang, CEO of OSRH. "We look forward to showcasing the strength of our platform, the progress we've made, and the catalysts ahead. We are committed to transparency, disciplined execution, and delivering meaningful value to all stakeholders in the coming months."Featured Speakers: Mr. Peter Hwang – Chief Executive Officer Dr. Constance Höfer – Chief Scientific Officer Mr. Tim Smith – Global Investor Relations About OSR Holdings, Inc. OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness to support global health outcomes. Through its subsidiaries, OSRH is engaged in immuno‑oncology, regenerative biologics, and medical device distribution. OSRH's vision is to acquire and operate a portfolio of innovative healthcare and wellness companies, improving patient care through cutting‑edge research and development. For more information, visit View original content to download multimedia: SOURCE OSR Holdings Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
4 hours ago
- Yahoo
Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference
Presentations to include efficacy, safety and opioid use reduction data in two different surgery models as well as pharmacokinetics data PITTSBURGH, Aug. 1, 2025 /PRNewswire/ -- Viatris (Nasdaq: VTRS), a global healthcare company, today announced that five abstracts from its Phase 3 program evaluating novel fast-acting formulation of meloxicam (MR-107A-02) in moderate-to-severe acute surgical pain models will be presented at the PAINWeek 2025 national conference in Las Vegas from September 2-5, 2025. The presentations will include positive results from two previously announced pivotal studies in herniorrhaphy (NCT06215859) and bunionectomy (NCT06215820) surgery models. All accepted scientific abstracts are now available on the PAINWeek website. Full List of Viatris Presentations at PAINWeek 2025 Poster Title Presentation Details Poster #41 Pharmacokinetics study comparing MR-107A-02 (novel fast-acting meloxicam formulation) 15mg tablet with meloxicam (Mobic®) 15mg in healthy adult male subjects. Live Abstract Presentation Thursday, Sept. 4 4:35 p.m. - 4:45 p.m. PDT Poster #39 Efficacy and safety of MR-107A-02 (novel fast-acting meloxicam formulation) for the treatment of acute moderate-to-severe pain following bunionectomy Live Abstract Presentation Thursday, Sept. 4 4:50 p.m. - 5:00 p.m. PDT Poster #38 Efficacy and safety of MR-107A-02 (novel meloxicam fast-acting formulation) for the treatment of acute moderate-to-severe pain following herniorrhaphy. Live Abstract Presentation Thursday, Sept. 4 5:05 p.m. - 5:15 p.m. PDT Poster #40 Opioid sparing effect of MR-107A-02 (novel fast-acting meloxicam formulation) for the treatment of acute moderate-to-severe pain following bunionectomy and herniorrhaphy. Live Abstract Presentation Thursday, Sept. 4 5:20 p.m. - 5:30 p.m. PDT Poster #76 Efficacy and Safety of a Rapid-Absorption Formulation of Meloxicam in the Treatment of Acute Postoperative Pain Following Bunionectomy and Herniorrhaphy Poster presentation only About Viatris Viatris (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at and and connect with us on LinkedIn, Instagram, YouTube and X. Forward-Looking StatementsThis press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements that about the results of clinical trials. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the uncertainties inherent in research and development, including the outcomes of clinical trials; the ability to meet anticipated clinical endpoints; the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from clinical studies; actions and decisions of healthcare and pharmaceutical regulators; our ability to comply with applicable laws and regulations; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market; products in development and/or that receive regulatory approval may not achieve expected levels of market acceptance, efficacy or safety; longer review, response and approval times as a result of evolving regulatory priorities and reductions in personnel at health agencies; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings on Viatris; Viatris' failure to achieve expected or targeted future financial and operating performance and results; goodwill or impairment charges or other losses; any changes in or difficulties with the Company's manufacturing facilities; risks associated with international operations; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties regarding future demand, pricing and reimbursement for the Company's products; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions, potential adverse impacts from future tariffs and trade restrictions, inflation rates and global exchange rates; and the other risks described in Viatris' filings with the Securities and Exchange Commission ("SEC"). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law. View original content to download multimedia: SOURCE Viatris Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
